Business
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
Appointed Mark Nawacki, seasoned M&A expert, co-founder, president & former CEO of Search...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors\n\n\n .bwlistdisc { list-style-type: disc }\n \n\n\n\n\n\n Appointed Mark Nawacki, seasoned M&A expert, co-founder, president & former CEO of Searchlight Pharma, to Board of Directors\n \n\n\n\n Completed IND submission to the U.S. FDA and global regulatory filings to advance a Phase 2 clinical trial of SAT-3247 in children with Duchenne muscular dystrophy (DMD)\n \n\n\n\n Dosed first patient in open-label, long-term follow-up study (LT-001) of SAT-3247 in adults with DMD\n \n\n\n\n Ended the third quarter of 2025 with cash balance of $48.2 million ($34.6 million in $U.S.)\n \n\n\n\n\n\n Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced its financial results for the third quarter ended September 30, 2025, and other corporate and clinical updates.\n \n\n “The second half of 2025 represents another important milestone for Satellos as we advance toward initiating the global Phase 2 pediatric study of SAT-3247 and continue to generate meaningful data in adults with Duchenne,” said Wildon Farwell, M.D., Satellos chief medical officer. “With multiple regulatory submissions completed and our long-term adult clinical study LT-001 now underway, our focus is firmly on clinical execution for these patients.”\n \n\n As Satellos advances its clinical programs and matures as an organization, the Company is also taking steps to ensure alignment with its long-term value strategy. This includes maintaining a strong and independent Board of Directors with the experience to guide the next phases of development and growth.\n \n\n “We are pleased to strengthen our strategic leadership with the addition of Mark Nawacki to the Board of Directors,” said Frank Gleeson, co-founder and chief executive officer of Satellos. “Mark’s extensive experience founding and developing organizations through disciplined growth, acquisitions, and licensing will add valuable perspective as we prepare for the next stage of SAT-3247 development and Satellos’ continued growth.”\n \n\n\n CORPORATE UPDATE\...